Director/PDMR share purchase
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 20 December 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), which is commercialising the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment for chronic kidney disease, announces that Fergus Fleming, Chief Technology Officer and Executive Director, has today bought 25,000 ordinary shares of £0.0025 each ("Ordinary Shares") in the Company at a price of £0.0975 per Ordinary Share.
Following this transaction, Fergus Fleming is interested in 594,481 Ordinary Shares representing 0.18% of the issued share capital of the Company.
| a) | Name | Fergus Fleming |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Technology Officer & Executive Director |
| b) | Initial notification /Amendment | Initial Notification |
| a) | Name | Renalytix plc |
| b) | LEI | 213800NTOH3FK3WER551 |
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.0025 each |
| Identification code | GB00BYWL4Y04 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| £0.0975 | 25,000 | |
| d) | Aggregated information | |
| - Aggregated volume | 25,000 | |
| - Price | £0.0975 | |
| e) | Date of the transaction | 20 December 2024 |
| f) | Place of the transaction | London Stock Exchange, AIM |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.